Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada)

PHASE3TerminatedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

March 25, 2020

Primary Completion Date

August 17, 2020

Study Completion Date

August 17, 2020

Conditions
Corona Virus InfectionSARS-CoV InfectionCoronavirus
Interventions
DRUG

Hydroxychloroquine

200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days

DRUG

Placebo oral tablet

4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days

Trial Locations (8)

55455

University of Minnesota, Minneapolis

Unknown

University of Alberta, Edmonton

University of British Columbia, Vancouver

University of Manitoba, Winnipeg

Eastern Health, St. John's

McMaster University, Hamilton

Lawson Health Research Institute, London

H4A3J1

Research Institute of the McGill University Health Centre, Montreal

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

University of Manitoba

OTHER

collaborator

University of Alberta

OTHER

collaborator

University of British Columbia

OTHER

collaborator

McMaster University

OTHER

collaborator

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER

collaborator

Eastern Health

OTHER

collaborator

University of Minnesota

OTHER

lead

McGill University Health Centre/Research Institute of the McGill University Health Centre

OTHER